GSK was the market leader in 2006 with an 8.1% market share, while last year it ranked seventh with a 4.3% market share, according to the market research company Cegedim data.
“To us, a company with innovative drugs, the freeze of the subsidized drug list (2008-2014 i.e.) had a significant impact on the opportunities to put new products on the market for more than six years. Furthermore, our change of global strategy led to significant changes in GSK’s business model and our product portfolio,” Petru Gradinariu, corporate affairs and communication manager of GlaxoSmithKline Romania, told ZF.
“For instance, we’ve dropped certain portfolios such as antithrombotics, vitamins and cancer products.”
New products have only been added to the subsidized drug list in the past two years, he added.
Pharmaceutical drug sales stood at 11.7 billion lei (EUR2.6 billion) in Romania in 2015, 4.7% lower than in 2014, according to Cegedim data. This was the first decline of the market in ten years. (EUR1=RON4.4774)
(English version by Loredana Fratila-Cristescu)